PHA-Exchange> Sources of Affordable Generic Medicines Drying Up?

[claudio at hcmc.netnam.vn]

Sources of Affordable Generic Medicines Drying Up?
--------------------------------------------------

India Should Ensure Global Access to Medicines When Amending Its
Patent Law

MSF Press Release
Doctors Without Borders/Medecins Sans Frontieres (MSF)

For Immediate Release
Contact: Kris Torgeson, +1-212-655-3764

Geneva, 15 March 2005 - As the Indian Parliament prepares to
tackle the country's implementation of the World Trade Organiza-
tion's (WTO) agreement regulating patents on medicines, Doctors
Without Borders/Medecins Sans Frontieres (MSF) is urging Indian
decision makers to ensure that patients in developing countries
will continue to have access to affordable medicines.

"MSF has examined the proposed amendments to India's Patents Act
of 1970. We believe they will drastically restrict, perhaps even
prevent, the production and supply of vital therapies by Indian
pharmaceutical companies to other developing countries," said
Ellen 't Hoen, director of policy advocacy and research with
MSF's Campaign for Access to Essential Medicines.

In the past few years, India has played a pivotal role in sup-
plying affordable generic versions of medicines used throughout
the developing world. It has also been a leader in the debates
on patent barriers to access to medicines at the WTO, fighting
for measures in international patent rules that protect public
health. But the country's obligation under WTO law to grant 20-
year patents on pharmaceutical products may be putting this
reputation at risk unless Indian politicians use their power
wisely. The lives of millions of people worldwide using afford-
able Indian medicines depend on India's future policies with re-
gard to medicines patents.

Nowhere is this more visible than in the case of HIV/AIDS treat-
ment. Of the 700,000 people currently receiving antiretroviral
treatment in developing countries, an estimated 50% rely on In-
dian generic production. MSF now treats 25,000 people with an-
tiretrovirals in 27 countries around the world, and roughly 70%
of the patients in those programs use medicines that originate
in India. Before generic drugs became widely available in 2001,
similar treatments cost over US$ 10,000 per patient per year -
40 times more than the average price of ARV treatment in MSF
programs today (US$ 250). The availability of affordable fixed-
dose combination therapy, or three-in-one pills, manufactured in
India has revolutionized AIDS treatment in developing countries.

But providing this user-friendly form of treatment has only been
possible because there are no patent constraints in India on
combining these medicines in one tablet. After India and other
developing countries with manufacturing capacity start granting
patents, generic drug manufacturers can no longer produce ge-
neric versions of patented drugs. Most new drugs are likely to
be patented, so sources of new low-cost medicines will dry up
globally.

It is crucial that India allows production and export of generic
versions of new medicines in the future. MSF urges Indian policy
makers to ensure that the proposed amendments to the 1970 Patent
Act incorporate the full flexibilities and safeguards of the
TRIPS Agreement and reflect the hard-fought outcome of the Doha
Declaration on TRIPS and Public Health, which affirmed that "the
TRIPS Agreement can and should be interpreted and implemented in
a manner supportive of WTO Members' rights to protect public
health and, in particular, to promote access to medicines for
all."

"MSF hopes that India will continue to demonstrate the kind of
international leadership it has shown with the WTO Doha Declara-
tion on TRIPS and Public Health thus far," 't Hoen said. "Any
amendments to the country's new patent law must safeguard not
only the citizens of India, but also the millions of children,
women and men in the developing world whose lives depend on ac-
cess to affordable generic medicines."

To download MSF briefing documents on this topic, click on the
links below

"Will the Lifeline for Affordable Medicines Be Cut? Consequences
of Medicines Patenting in India"
http://www.accessmed-msf.org/documents/India%20briefing%20note%20Feb%2024%
20FINAL.doc

"The Effects of the 2005 TRIPS Implementation Deadline on Access
to Medicines"
http://www.accessmed-msf.org/documents/technical%202005%20briefing%20Feb%2024%
20FINAL.doc

For additional information, go to:
http://www.accessmed-msf.org/index.asp

--
Rachel M. Cohen
U.S. Director, Campaign for Access to Essential Medicines
Doctors Without Borders/Médecins Sans Frontières (MSF)
mailto:rachel.cohen at newyork.msf.org
http://www.doctorswithoutborders.org/
http://www.accessmed-msf.org/
_______________________________________________


------------------------------------------------------------------
This mail sent through Netnam-HCMC ISP: http://www.hcmc.netnam.vn/